SCHEMBL7559508

SCHEMBL7559508

O=C(C(=O)c1ccnc(F)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.70
CNR2 P34972 1/20 0.51
TLR7 Q9NYK1 4/20 0.49
NPSR1 Q6W5P4 2/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
HSD17B10 Q99714 1/20 0.48
LMNA P02545 2/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
SRD5A2 P31213 1/20 0.48
ABL1 P00519 1/20 0.47
BCR P11274 1/20 0.47
KCNQ3 O43525 1/20 0.46
KCNQ2 O43526 1/20 0.46
KCNE1 P15382 1/20 0.46
KCNQ1 P51787 1/20 0.46
KCNQ5 Q9NR82 1/20 0.46
P2RX1 P51575 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027246 0.88 CES2 (0.54) CES2CNR2TLR7NPSR1ALOX15
SCHEMBL4027250 0.88 CES2 (0.54) CES2CNR2TLR7NPSR1ALOX15
SCHEMBL3176325 0.83 CES2 (1.00) CES2NPSR1LMNAPOLBHPGD
SCHEMBL4030893 0.83 CES2 (0.77) CES2CNR2TLR7NPSR1ALOX15
SCHEMBL4600071 0.79 MAPT (0.70) TSHRLMNAPOLBKCNQ3KCNQ2
SCHEMBL4025014 0.79 DDR1 (0.52) CES2CNR2TLR7NPSR1ALOX15
SCHEMBL4848676 0.79 CES2 (0.89) CES2NPSR1LMNAPOLBHPGD
SCHEMBL10841345 0.77 CES2 (0.72) CES2NPSR1ALOX15TSHRCASP1
SCHEMBL29923199 0.75 CES2 (0.81) CES2NPSR1LMNAPOLBHPGD
SCHEMBL4171698 0.75 CES2 (0.81) CES2NPSR1LMNAPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1131314-A4 COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2002-05-02 EP disclosed
US-6350744-B1 PYRMIDINE OR PYRIDINE DERIVATIVES; ANTIARTHRITIC AND ANTIINFLAMMATORY AGENTS; CACHEXIA TREATMENT; INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS MERCK & CO., INC. 2002-02-26 US disclosed
EP-1131314-A1 COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 2001-09-12 EP disclosed
WO-2001022965-A1 SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 2001-04-05 WO disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed
WO-2000031065-A1 COMPOUNDS HAVING CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 2000-06-02 WO disclosed
EP-0854870-A4 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 1999-01-07 EP disclosed
EP-0854870-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY Merck & Co., Inc. (US) 1998-07-29 EP disclosed
WO-1997012876-A1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO., INC. (US) 1997-04-10 WO disclosed